Diagnosis and Management of Synchronous Prostate and Rectal Cancer in a Patient

Sep 23, 2026

The management of synchronous prostate and rectal cancer is difficult because the tumors are anatomically close and shared treatment planning lacks standardization. This open access case report reviews an Epic chart review of a 70-year-old man presenting urinary frequency, weak stream, and nocturia. MRI and transrectal biopsy confirmed intermediate-risk stage IIC prostate adenocarcinoma, while colonoscopy and subsequent MRI/pathology identified stage IIIB colonic adenocarcinoma. Treatment used leuprolide and bicalutamide, then VMAT to rectum/prostate/lymph nodes, rectum/prostate, followed by prostate with concurrent capecitabine.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages7

Reading Time18 min

AccessFree to download

Abstract

Introduction

Case Presentation

Diagnosis

(Further sections not provided in the excerpt)

Received 08/07/2025 Review began 10/24/2025 Review ended 03/05/2026 Published 03/13/2026 © Copyright 2026 Iqbal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited. DOI: 10.7759/cureus.105182 Open Access Case Report Published via Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) Diagnosis and Management of Synchronous Prostate and Rectal Cancer in a Patient Hamail Iqbal 1, Nilanjan Haldar 2 , Adam C. Mueller 2 1. Department of Medicine, Cooper Medical School of Rowan University, Camden, USA 2. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, USA Corresponding author: Adam C. Mueller, [adam.mueller@pitt.edu](adam.mueller@pitt.edu) Abstract The management of the synchronous occurrence of prostate and rectal cancer presents a challenge due to their anatomic proximity. Considering the high morbidity and mortality of malignancies individually, welltargeted treatment planning is required for optimal survival outcomes; however, management strategies have not been standardized. We describe the diagnosis and treatment of synchronous prostate and rectal cancer in a single patient. An Epic chart review of a 70-year-old man with synchronous prostate and rectal cancer was completed. The patient presented with urinary frequency, weak urinary stream, and nocturia. Magnetic resonance imaging (MRI) and transrectal biopsy confirmed intermediate-risk, stage IIC prostate adenocarcinoma. Concurrently, findings suspicious for malignancy were identified on screening colonoscopy. MRI and pathology confirmed stage IIIB colonic adenocarcinoma. Initial treatment for the prostate cancer was begun with leuprolide and bicalutamide. Subsequently, the patient was prescribed volumetric modulated arc therapy (VMAT) to the rectum, prostate, and lymph nodes; followed by the rectum and prostate; and finally the prostate. The patient received concurrent capecitabine. When treating synchronous malignancies, an integrated approach is necessary to minimize the length of intervention and adverse events. Compared to the serial treatment of rectal and prostate cancer, concurrent treatment with the expansion of the target volume has demonstrated decreased risk of wound complications and comparable disease-free survival. Further long-term follow-up and monitoring are needed to establish standard management strategies for synchronous prostate and rectal cancer. Categories: Therapeutics, Radiation Oncology, Oncology Keywords: chemoradiation, field cancerization, prostate cancer, radiation therapy, rectal cancer Introduction Prostate and rectal cancer are among the leading cancer diagnoses in men. Prostate cancer is the second leading cause of cancer-related death among men worldwide, with more than one million new cases diagnosed annually [1] . Rectal cancer, which accounts for roughly one-third of all colorectal cancers, also represents a major contributor to global cancer morbidity and mortality [1] . Due to the anatomic proximity of these two structures and their overall incidence in older patients, there is a moderate potential of individuals having both cancers within their lifetime [2-4]. However, the synchronous occurrence of prostate and rectal cancer, defined as both cancers diagnosed within a short interval, is exceedingly rare. A population-based registry from Sweden estimated an incidence of 0 . 1% among patients diagnosed with either rectal or prostate cancer between 1995 and 2011 [5] . More recent Swedish registry data indicate that among patients with prostate cancer from 1993 to 2019, 0.25% had synchronous rectal cancer, with agestandardized incidence rates rising over time [6] . Multi-institutional data from the United States also suggest an incidence of 0 . 17% using a broade

FAQs

Why are synchronous prostate and rectal cancers challenging to manage?

Overlapping pelvic anatomy and the need to stage two distinct malignancies create diagnostic and therapeutic conflicts. The absence of standardized guidelines further increases complexity.

How were the cancers diagnosed in the reported patient?

MRI and transrectal biopsy confirmed intermediate-risk stage IIC prostate adenocarcinoma. Screening colonoscopy followed by MRI and pathology confirmed stage IIIB colonic adenocarcinoma.

What treatment approach was used for the synchronous disease?

Initial prostate-directed therapy used leuprolide and bicalutamide, followed by VMAT delivering radiation to the rectum, prostate, and lymph nodes, then rectum/prostate, and finally prostate. Concurrent capecitabine was administered.

Sep 23, 2026

Uploaded by Sophia Brooks